Drugs / MK0916
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00274716 | Nov 2005 → Jan 2007 | hypertensive disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00543595 | Aug 2004 → May 2005 | metabolic syndrome X, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0916 | “This study evaluated the antihypertensive efficacy and safety of two 11β-HSD1 inhibitors, MK-0736 and MK-0916, in overweight-to-obese hypertensive patients.” PMID 21419745 ↗ Mar 20113“Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome.” PMID 21272190 ↗ Jun 2011 |
| Action | Inhibit | “two 11β-HSD1 inhibitors” PMID 21419745 ↗ Mar 2011 |
| Target | HSD11B1 | “This study evaluated the antihypertensive efficacy and safety of two 11β-HSD1 inhibitors, MK-0736 and MK-0916, in overweight-to-obese hypertensive patients.” PMID 21419745 ↗ Mar 2011 |